Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

On Monday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $26.24 which represents a slight increase of $0.01 or 0.04% from the prior close of $26.23. The stock opened at $26.23 and ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

On Wednesday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $29.35 which represents a slight increase of $0.85 or 2.98% from the prior close of $28.5. The stock opened at $28.7 and ...

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

On Monday, Exelixis Inc . (NASDAQ:EXEL) maintained its Equal Weight rating and a $23.00 stock price target according to Stephens. The decision comes as Exelixis announced a significant clinical ...